The slated therapy for the deviated septum is, of course, the nose job – but outside of surgery and some clunky breathing devices, there aren’t too many options for nasal disorders that stem from severe congestion or allergic rhinitis.
Aerin Medical just closed a $16.7 million Series C to craft an interesting solution to the issue – using non-ablative radiofrequency energy to target and remodel the structural and mucosal tissues that cause nasal congestion. Meaning, its “Aerin Medical Wand” doesn’t destroy the tissues present, as an ablative device might – it simply morphs their structure so their engineering is a touch more conducive to breathing. Aerin’s procedure is meant to be conducted in a physician’s office.
The first $6.1 million of the round comes from the Targeted Technology Fund, and the second $10.6 million comes from KCK Group.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Aerin has conducted study in some 100 patients in the U.S. and Europe, it said in a release, and has found “Aerin’s treatments are able to quickly alleviate symptoms with minimal patient discomfort and durable results.” It’s a treatment meant to bridge the gap between medical management and surgical interventions for a large group of patients, CEO Fred Dinger said in the statement.
A 33-patient U.S. trial launched in 2013 is slated to wrap up next month, according to its listing on ClinicalTrials.gov.
